The present invention discloses a non-acidic-candy based composition for arresting or reversing dental caries by transforming the oral cavity from an acidic, bacteria-filled environment to an environment more conducive to remineralization by quickly neutralizing the acids recreated by ingestion of acidic compounds or by cariogenic bacteria while supplying necessary ions for tooth remineralization. This improves oral health, prevents pain and suffering, and serves as a conduit to deliver additional therapeutic agents. The composition comprises any combination of a calcium-based compound, a bicarbonate compound, a fluoride compound, an active ingredient, a therapeutic agent based on need, a non-cariogenic sweetener, a hydrating agent, at least one additive, and water. The composition is a candy that has a non-acidic-based composition which neutralizes acids while delivering necessary ions in a pH optimized environment to create the best possible conditions needed to arrest and/or reverse disease processes in the oral cavity and beyond.

The present invention discloses a non-acidic-candy based composition for arresting or reversing dental caries by transforming the oral cavity from an acidic, bacteria-filled environment to an environment more conducive to remineralization by quickly neutralizing the acids recreated by ingestion of acidic compounds or by cariogenic bacteria while supplying necessary ions for tooth remineralization. This improves oral health, prevents pain and suffering, and serves as a conduit to deliver additional therapeutic agents. The composition comprises any combination of a calcium-based compound, a bicarbonate compound, a fluoride compound, an active ingredient, a therapeutic agent based on need, a non-cariogenic sweetener, a hydrating agent, at least one additive, and water. The composition is a candy that has a non-acidic-based composition which neutralizes acids while delivering necessary ions in a pH optimized environment to create the best possible conditions needed to arrest and/or reverse disease processes in the oral cavity and beyond.

The present invention discloses a non-acidic-candy based composition for arresting or reversing dental caries by transforming the oral cavity from an acidic, bacteria-filled environment to an environment more conducive to remineralization by quickly neutralizing the acids recreated by ingestion of acidic compounds or by cariogenic bacteria while supplying necessary ions for tooth remineralization. This improves oral health, prevents pain and suffering, and serves as a conduit to deliver additional therapeutic agents. The composition comprises any combination of a calcium-based compound, a bicarbonate compound, a fluoride compound, an active ingredient, a therapeutic agent based on need, a non-cariogenic sweetener, a hydrating agent, at least one additive, and water. The composition is a candy that has a non-acidic-based composition which neutralizes acids while delivering necessary ions in a pH optimized environment to create the best possible conditions needed to arrest and/or reverse disease processes in the oral cavity and beyond.

The present invention refers to reagents and methods for preparing a peptide sequence having a [.sup.18F]fluoro-aromatic amino acid side which may be further substituted, in particular a 4-[.sup.18F]fluoro-phenylalanine side chain in peptide sequences, by chemoselective radio-deoxyfluorination of an aromatic amino acid residue, in particular a tyrosine residue using a traceless-activating group and the reagents used in said process.

Stable and durable polymeric microbubbles of a 1-10 μm size range are disclosed. The microbubbles are synthesized from the co-polymer poly lactic-co-glycolic acid (PLGA), which provides a plurality of PLGA microbubbles presenting diverse cavitation activities. The PLGA microbubbles are particularly suitable for cavitation enhancement purposes and are applicable in various clinical procedures such as ablation or enhancement of uptake of chemical or biological therapy in cells and tissue.

Stable and durable polymeric microbubbles of a 1-10 μm size range are disclosed. The microbubbles are synthesized from the co-polymer poly lactic-co-glycolic acid (PLGA), which provides a plurality of PLGA microbubbles presenting diverse cavitation activities. The PLGA microbubbles are particularly suitable for cavitation enhancement purposes and are applicable in various clinical procedures such as ablation or enhancement of uptake of chemical or biological therapy in cells and tissue.

The present disclosure relates to a composition for increasing the expression of a blood coagulation factor gene, which contains core-shell structured microparticles as an active ingredient. When administered in vivo along with blood coagulation factor VIII gene or a variant gene thereof, the composition for increasing the expression of a blood coagulation factor gene of the present disclosure can increase the expression of the gene by at least 30%. When administered along with a gene therapeutic agent, the composition can achieve a therapeutic effect even with a very small amount of a gene, and thus is useful.

The present disclosure relates to a composition for increasing the expression of a blood coagulation factor gene, which contains core-shell structured microparticles as an active ingredient. When administered in vivo along with blood coagulation factor VIII gene or a variant gene thereof, the composition for increasing the expression of a blood coagulation factor gene of the present disclosure can increase the expression of the gene by at least 30%. When administered along with a gene therapeutic agent, the composition can achieve a therapeutic effect even with a very small amount of a gene, and thus is useful.

The present invention relates to compositions and methods to treat and/or prevent biofilms and biofilm related diseases. The invention comprises a nanoparticle carrier (NPC) and at least one therapeutic agent therein. The NPC binds within biofilm and to surfaces at risk for biofilm formation and accumulation while providing local, sustained, enhanced and controlled delivery of the therapeutic agent, when triggered for release. In one embodiment, the NPC comprises pH-responsive elements that allows for specific delivery of the therapeutic agent when the local environment dictates that the agent should be delivered precisely when it is most needed.

The present invention relates to compositions and methods to treat and/or prevent biofilms and biofilm related diseases. The invention comprises a nanoparticle carrier (NPC) and at least one therapeutic agent therein. The NPC binds within biofilm and to surfaces at risk for biofilm formation and accumulation while providing local, sustained, enhanced and controlled delivery of the therapeutic agent, when triggered for release. In one embodiment, the NPC comprises pH-responsive elements that allows for specific delivery of the therapeutic agent when the local environment dictates that the agent should be delivered precisely when it is most needed.